Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Florian Nolte*, Emanuele Angelucci, Photis Beris, Alan Macwhannell, Dominik Selleslag, Christiane Schumann, Blanca Xicoy, António Almeida, Agnés Guerci-Bresler, Thamer Sliwa, Petra Muus, John Porter, Wolf K. Hofmann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.
Original languageEnglish
Pages (from-to)1131-1135
Number of pages5
JournalLeukemia Research
Volume35
Issue number9
DOIs
Publication statusPublished - Sep 2011
Externally publishedYes

Keywords

  • Chelation
  • Deferasirox
  • Gastrointestinal disturbances
  • Iron overload
  • Myelodysplastic syndrome
  • Transfusion

Fingerprint

Dive into the research topics of 'Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox'. Together they form a unique fingerprint.

Cite this